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ORIGINAL ARTICLE
Speciﬁc gut microbiota features and metabolic markers in
postmenopausal women with obesity
LK Brahe1,4, E Le Chatelier2,4, E Prifti2, N Pons2, S Kennedy2, T Hansen3, O Pedersen3, A Astrup1, SD Ehrlich2 and LH Larsen1
BACKGROUND: Gut microbial gene richness and speciﬁc bacterial species are associated with metabolic risk markers in humans,
but the impact of host physiology and dietary habits on the link between the gut microbiota and metabolic markers remain
unclear. The objective of this study was to identify gut metagenomic markers associated with estimates of insulin resistance, lipid
metabolism and inﬂammation in obesity, and to explore whether the associations between metagenomic and metabolic markers
persisted after adjustment for body fat, age and habitual dietary intake.
METHODS: Faecal DNA from 53 women with obesity was analysed through quantitative metagenomic sequencing and analysis,
and a systematic search was performed for bacterial genes associated with estimates of insulin resistance, inﬂammation and lipid
metabolism. Subsequently, the correlations between metagenomic species and metabolic markers were tested by linear regression
models, with and without covariate adjustment.
RESULTS: One hundred and fourteen metagenomic species correlated with metabolic markers (Po0.001) including Akkermansia
muciniphila, Bilophila wadsworthia, Biﬁdobacterium longum and Faecalibacterium prausnitzii, but also species not previously
associated with metabolic markers including Bacteroides faecis and Dorea longicatena. The majority of the identiﬁed correlations
between bacterial species and metabolic markers persisted after adjustment for differences in body fat, age and dietary
macronutrient composition; however, the negative correlation with insulin resistance observed for B. longum and F. prausnitzii
appeared to be modiﬁed by the intake of dietary ﬁbre and fat, respectively.
CONCLUSIONS: This study shows that several gut bacterial species are linked to metabolic risk markers in obesity, also after
adjustment for potential confounders, such as long-term diet composition. The study supports the use of gut metagenomic
markers for metabolic disease prediction and warrants further investigation of causality.
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INTRODUCTION
The human gut hosts trillions of microbes with a collective genome
(the gut microbiome) that consists of nearly 10 million genes,1 which
exceeds more than 400-fold the size of the human genome that
consists of approximately 23 000 genes.2 This vast gut microbiome
provides the human host with vital functions that affect nutritional
efﬁciency and overall health.3 Metagenomic studies have suggested
that individuals with a metabolic risk proﬁle are characterized by low
gut microbiome richness,4,5 and negative correlations have been
found between bacterial gene count and metabolic risk markers in
the present cohort of postmenopausal women with obesity.6
Additionally, studies have shown that microbial gene markers
correlate better with type-2 diabetes (T2D) than both anthropo-
metric risk markers7 and common variation in the human genome.8
Thus, the gut microbiome has been proposed as a marker for early
identiﬁcation of individuals at increased risk of obesity-related
metabolic diseases.5
The gut microbiota develops immediately after birth inﬂuenced
by delivery mode, early nutrition and host genotype,3 and within
the ﬁrst 3 years of life, the microbial diversity reaches a level
similar to adulthood.9 The composition of the adult gut microbiota
is considered overall stable.10 Yet, several factors modulate the
adult gut microbiota including age, antibiotics and diet.3 A
modulating effect of dietary intake on the gut microbiota has
been shown by the impact of long-term dietary habits,9,11,12
changes in macronutrient composition13 and shifts in intake of
animal- versus plant-based diets.14 In addition, the relative
abundance of bacterial species and the microbial diversity vary
with the physiological state of the host, shown by the altered gut
microbiota in pregnancy,15 inﬂammatory bowel disease,16
obesity,17 T2D,8 atherosclerosis,18 non-alcoholic fatty liver
disease19 and liver cirrhosis.20
The impact of host physiology and dietary habits on the link
between the gut microbiota and metabolic markers remains
uncertain. One study that identiﬁed an inverse correlation
between gut microbial gene richness and metabolic risk in
humans also recognized that individuals with low bacterial
richness (o480 000 bacterial genes) consumed less fruit,
vegetables and ﬁsh, compared to individuals with high bacterial
richness.4 In addition, large differences have been reported in the
prevalence of low bacterial richness in obese individuals at
increased metabolic risk; ranging from 8%6 to 40%,4 which could
be due to variation in dietary habits.
The objective of this study was to identify gut metagenomic
markers associated with insulin resistance, lipid metabolism and
inﬂammation in obese women, and to explore whether the
associations between metagenomic and metabolic markers
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persisted after adjustment for differences in age, body fat and
habitual dietary intake.
SUBJECTS AND METHODS
Study design and participants
This study includes baseline data from 53 participants who completed
a dietary intervention with intake of Lactobacillus paracasei F19, ﬂaxseed
mucilage or placebo over 6 weeks.6 The study took place at the Department
of Nutrition, Exercise and Sports (NEXS), Faculty of Sciences, University of
Copenhagen, Denmark, from September 2011 to September 2012. Written
informed consent was obtained from all participants; the study was approved
by the Ethical Committee for the Capital Region of Denmark (journal H-3-
2011-067) in accordance with the Helsinki II Declaration and registered at
ClinicalTrial.gov (NCT01433120). The study included postmenopausal women
with a body mass index (BMI) of 30–45 kgm−2. Exclusion criteria were
gastrointestinal diseases, chronic diseases as type-1 diabetes or liver cirrhosis,
medically-treated T2D or dyslipidaemia, intake of antibiotics, supplementary
pro- or prebiotics or high quantities of fermented foods (4400 g day−1) in
the previous months.
Anthropometric and biochemical measurements
Anthropometric and biochemical measurements were obtained after an
overnight fast. Body composition was assessed by dual-energy X-ray
absorptiometry (DXA) (iDXA, Lunar Radiation Co., Madison, WI, USA), BMI
(kgm−2), waist circumference and intra-abdominal adipose tissue (IAAT
cm2: − 208.2+4.62 (sagittal diameter, cm)+0.75 (age, years)+1.73 (waist, cm)
+0.78 (trunk fat %)).21 An oral glucose tolerance test was performed and
insulin sensitivity was assessed by plasma glucose, serum insulin and
C-peptide at the fasting and stimulated state. Insulin resistance was
estimated by homeostatic model assessment of insulin resistance (HOMA-
IR) (F-glucose (mmol l− 1) × F-insulin (mU l− 1)/22.5).22 Data from the oral
glucose tolerance test were evaluated by area under the curve (AUC)
analysis and by Matsudas index (10 000 / √ (F-glucose (mg dl− 1) ×
F-insulin (mU l− 1) × (mean oral glucose tolerance test glucose×mean oral
glucose tolerance test insulin)).23
Inﬂammatory status was assessed by white blood cell (WBC) count,
fasting concentration of plasma high sensitive C-reactive protein (hsCRP),
lipopolysaccharide-binding protein (LBP), cluster of differentiation 14 (CD14),
and serum concentrations of the liver enzymes aspartate aminotransferase
(AST) and alanine aminotransferase (ALT). Lipid metabolism was assessed by
fasting concentrations of serum total cholesterol, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides
(TAG) and plasma concentrations of free fatty acids (FFAs).
Blood for analysis of CD14 and FFA was drawn in iced tubes pre-coated
with EDTA. Blood for analysis of AST and ALT was collected in plain tubes.
Blood samples were centrifuged for 10min at 2500 g at 4 °C and kept at
− 80 °C until analyses were performed. ABX Pentra 400 (Horiba ABX,
Montpellier, France) was used to analyse blood concentrations of
FFA (intra- and inter-assay coefﬁcient of variability: 1.7 and 5.3%), ALT
(intra- and inter-assay coefﬁcient of variability: 3.1 and 6.0%) and AST
(intra- and inter-assay coefﬁcient of variability: 2.7 and 5.0%). CD14 (intra-
and inter-assay coefﬁcient of variability: 6.5 and 1.7%) was analysed with a
human Elisa kit (R&D Systems, Minneapolis, MN, USA). Details of all other
biochemical analyses have been described elsewhere.6
Dietary records
Registration of 3 days weighed dietary intake was performed within the
week before the baseline visit to obtain information about habitual dietary
habits. Dietary records were analysed by a registered dietician by use of a
dietary software program (Dankost Pro, Copenhagen, Denmark).
Microbiota analyses
Participants collected samples of stool within 2 days before the visit.
Samples were either stored immediately at − 80 °C or brieﬂy stored in a
− 18 °C freezer and kept frozen during the transport to the laboratory. Total
DNA from faecal samples was extracted, sequenced and analysed by
quantitative metagenomics at Metagenopolis (INRA, Jouy-en-Josas,
France), a detailed description of the metagenomic analysis is provided
elsewhere.6 DNA sequencing data were generated using the SOLiD 5500xl
sequencers (Life Technologies, Carlsbad, CA, USA). Primary data analyses
were performed using METEOR Studio pipeline for quantitative metage-
nomic proﬁling developed at INRA MetaGenoPolis based on the iMOMi
database. Reads generated from the SOLiD sequencer were trimmed to 35
bases then mapped by Bowtie software on the reference catalogue of 3.3
million genes.16 Microbial gene richness was measured by counting the
number of genes in a given sample by use of a downsized count matrix at
11 million unique reads as previously described.5 The exponential of
Shannon diversity index was included as a measure of alpha diversity.
A systematic search was performed for bacterial genes correlated with
metabolic markers and the bacterial genes were subsequently clustered
into metagenomic species (MGS) using the method based on binning
co-abundant genes across all individuals samples described elsewhere.5 A MGS
was assigned to a given genome when more than 80% of its genes matched
the same genome using blastN at a threshold of 95% identity over 90% of
gene length. The remaining MGSs were annotated using blastP analysis
and assigned to a given taxonomical level from genus to super kingdom
level if more than 80% of their genes had the same level of assignment.
Statistical analyses
The systematic search for bacterial genes that correlated with markers for
insulin sensitivity, lipid metabolism or inﬂammation was performed by use
of Spearman’s rank correlation coefﬁcient. Correction for multiple testing
was performed by the Benjamin–Hochberg method with the false
discovery rate at 5%. Correlations between a MGS and metabolic or
dietary markers are reported by Spearman's Rho (r) and P-values. In
addition, correlations between bacterial species and metabolic markers
were tested by linear regression analyses, with and without adjustment for
differences in age, body fat percentage and when applicable; the dietary
component with the strongest impact. Results from the regression models
are reported by Pearson’s correlation coefﬁcient (r) and P-values
(both adjusted and non-adjusted). Log transformation was applied to
non-normally distributed variables. Statistical signiﬁcance was attested at a
two-sided P-value of o0.05 and trend towards signiﬁcance was attested at
a P-value between 0.5 and 0.1. Analyses were performed using
MeatOMiner R package (developed at Metagenopolis, INRA, France) and
JMP version 9.0.2 (SAS Institute Inc, Cary, NC, USA).
RESULTS
Baseline data for the participants are reported in Table 1.
Of the 53 participants, 36 (68%) could be classiﬁed as metabolic
unhealthy, deﬁned as the presence of the metabolic syndrome,24
pre-diabetes or T2D.25
Gut bacteria associated with metabolic markers
A total of 55 069 bacterial genes correlated with metabolic markers
(Po0.001). In all, 31 134 genes (57%) could be clustered in 114
Figure 1. Heatmap of correlations between MGS and markers for insulin resistance, lipid metabolism, inﬂammation, body composition, dietary
intake and bacterial gene count. The heatmap reports signiﬁcant Spearman’s rank correlations (Po0.001) observed between 114 MGS signals
(rows) and 29 different markers (columns) using Euclidean distance metric and complete linkage method. Markers are grouped in ﬁve
categories given in the top of the ﬁgure: insulin resistance, lipid metabolism, inﬂammation, diet and others. MGS names are shown on the left
of the ﬁgure and their taxonomical annotation at the species or genus level is given on the right, coloured according to the phylum:
Firmicutes in black, Bacteroidetes in red, Actinobacteria in purple, Proteobacteria in blue, Verrucomicrobia in gold and Tenericutes in green.
The strength of the correlation is coloured according to the colour key in the upper left corner of the ﬁgure. ALT, alanine aminotransferase;
AST, aspartate aminotransferase; AUC, area-under-the-curve; BMI, body mass index; CD14, cluster of differentiation 14; F, fasting; FFAs, free
fatty acids; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitive C-reactive protein; HOMA-IR, homeostatic model assessment of
insulin resistance; IAAT, intra-abdominal adipose tissue; LBP, lipopolysaccharide-binding protein; LDL-C, low-density lipoprotein cholesterol;
TAG, triglycerides; Waist cir.; waist circumference; WBC, white blood cells.
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MGSs each with more than 50 microbial genes. Eighty-two MGSs
were assigned to a bacterial phylum and 32 MGSs were unknown.
Of the known MGSs; 55 were identiﬁed to species level. The MGS
abundance signals within the individuals, the size of the MGS and
the taxonomy data are given as Supplementary information.
The MGSs that were associated with insulin sensitivity,
inﬂammatory markers and lipid metabolism are presented in
Figure 1 and Supplementary Tables S1-S3. Bacteroides faecis,
Intestinibacter bartlettii, Biﬁdobacterium longum, F. prausnitzii
A2-165 and Dorea longicatena were negatively correlated with
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markers for insulin resistance, whereas Ruminococcus torques,
Clostridium bolteae, Eubacterium ramulus and Bilophila wads-
worthia were positively correlated (Supplementary Table S1).
Bacteroides pectinophilus was negatively correlated with inﬂam-
matory markers, whereas C. bolteae, Dorea formicigenerans, B.
wadsworthia, Roseburia hominis and F. prausnitzii SL3/3 were
positively correlated (Supplementary Table S2).
Odoribacter splanchnicus, B. pectinophilus, Bacteroides cellulosily-
ticus, Bacteroides nordii, Roseburia inulinivorans, Akkermansia
muciniphila, F. prausnitzii A2-165 and B. longum were associated
with a healthy fasting serum lipid proﬁle, deﬁned as a positive
correlation with HDL cholesterol or a negative correlation with
TAG, FFAs, total- or LDL cholesterol. Catenibacterium mitsuokai and
Holdemanella biformis were associated with an unhealthy fasting
serum lipid proﬁle (Supplementary Table S3).
Of the 32 unknown MGSs, 21 were associated with markers for
insulin resistance (mainly negative correlations), 27 were asso-
ciated with inﬂammatory markers (mainly negative correlations
with WBC) and 20 were associated with markers for lipid
metabolism (mainly negative correlations with total cholesterol
and TAG) (data not shown).
Link between bacterial species and metabolic markers after
covariate adjustment
The bacterial species that were linked to habitual dietary intake
(total energy, macronutrient composition, dietary ﬁbres) by
Spearman’s rank correlation are presented in Figure 1 and
Supplementary Table S4. Species associated with a healthy
metabolic proﬁle (Supplementary Tables S1-S3) were generally
negatively correlated with intake of dietary fat and positively
correlated with intake of carbohydrates, speciﬁcally dietary ﬁbres
(Supplementary Table S4), while the opposite was observed for
species associated with an unhealthy metabolic proﬁle. Microbial
gene richness and alpha diversity correlated positively with overall
protein intake (Supplementary Table S4), but when the types of
protein were considered, the correlations between proteins from
meat sources and microbial gene richness and alpha diversity
tended to be negative (r=− 0.25, P= 0.08 and r=− 0.27, P= 0.05,
respectively), while the correlations with proteins from sources
other than meat, including vegetables and ﬁsh were positive
(r= 0.27, P= 0.06 and r= 0.35, P= 0.01, respectively).
The majority of the associations between bacterial species and
metabolic markers persisted when tested by use of multiple linear
regression models with adjustment for differences in body fat, age
and associated dietary components (Supplementary Table S4). The
adjusted and non-adjusted results for these persistent associations
between bacterial species and relevant markers for insulin
resistance and dyslipidaemia are reported in Tables 2 and 3,
respectively.
Some identiﬁed associations between metagenomic and
metabolic markers were affected by the statistical adjustment;
the negative correlation between B. longum and markers for
insulin resistance disappeared after adjustment for intake of
carbohydrates, but the negative correlation with fasting glucose
persisted (Table 2). In addition, the negative correlation between
F. prausnitzii A2-165 and markers for insulin resistance disappeared
after adjustment for intake of fat.
DISCUSSION
This study shows that several gut bacterial species are linked to
metabolic risk markers in obesity after adjustment for the
potential confounders age, body fat and long-term diet composi-
tion, supporting the proposed use of gut metagenomic markers
for metabolic disease prediction and stratiﬁcation,5,7,8 and suggest-
ing that gut bacteria may have a causal role in the development of
obesity-related metabolic disease.
The species A. muciniphila, B. cellulosilyticus, B. faecis, B. nordii,
B. pectinophilus, I. bartlettii, D. longicatena, O. splanchnicus and
R. inulinivorans were all negatively associated with markers for
insulin resistance or dyslipidaemia, also after covariate adjustment,
suggesting a probiotic potential of these bacteria. Some of
these species have been linked to metabolic health previously;
B. pectinophilus has been found to be more abundant in lean
individuals, compared with obese,5 and the butyrate-producing
R. inulinivorans26 has been found to be more abundant in healthy
individuals, compared with individuals with T2D.8 A. muciniphila,
which was found to be negatively associated with serum total and
LDL cholesterol in the present study, is considered as the most
abundant mucolytic bacteria in healthy humans.27 A reduced
abundance of A. muciniphila could reﬂect a thin mucus layer and
thus an impaired gut barrier function with increased translocation
of pro-inﬂammatory bacterial toxins potentially leading to
metabolic disturbances. This mechanism is supported by the
reduced abundance of A. muciniphila observed in patients with
Table 1. Baseline characteristics
N 53
Metabolic healthy (N) 17
Metabolic unhealthy (N) 36
Age (years) 60 (6)
BMI (kgm−2) 34.5 (3.8)
Body fat (%) 47.0 (3.7)
Waist circumference (cm) 104.3 (9.3)
IAAT (cm2) 171 (29)
Insulin resistance
Fasting plasma glucose (mmol l− 1) 5.8 (0.8)
Fasting serum insulin (pmol l− 1) 93.2 (52.3)
Fasting serum C-peptide (pmol l− 1) 843 (336)
AUC glucose (mmol l− 1 per minute) 7.2 (1.5)
AUC insulin (pmol l− 1 per minute) 414 (243)
AUC C-peptide (pmol l− 1 per minute) 2777 (1020)
HOMA-IR 4.2 (2.6)
Matsudas index 2.4 (1.6)
Inﬂammatory markers
WBC (109 per litre) 5.5 (1.2)
Fasting plasma hsCRP (mg l− 1) 3.6 (3.5)
Fasting plasma LBP (μg l− 1) 19.0 (6.4)
Fasting plasma CD14 (ngml− 1) 1719 (269)
Liver enzymes
Fasting serum ALT (U l− 1) 17.3 (10.1)
Fasting serum AST (U l− 1) 21.0 (6.6)
Lipid metabolism
Fasting serum total cholesterol (mmol l− 1) 6.1 (0.9)
Fasting serum HDL cholesterol (mmol l− 1) 1.5 (0.3)
Fasting serum LDL cholesterol (mmol l− 1) 3.8 (0.8)
Fasting serum TAG (mmol l− 1) 1.4 (0.7)
Fasting plasma FFAs (μmol l− 1) 647 (161)
Dietary intake
Total energy intake (kJ day− 1) 7572 (1797)
Protein (E%) 18.9 (3.6)
Carbohydrates (E%) 40.8 (6.8)
Dietary ﬁbres (g day− 1) 21.3 (6.0)
Fat (E%) 35.3 (6.3)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; AUC, area under the curve; BMI, body mass index; CD14, cluster of
differentiation 14; E%, energy percentage; FFAs, free fatty acids; HDL, high-
density lipoprotein; hsCRP, high sensitive C-reactive protein; HOMA-IR,
homeostatic model assessment of insulin resistance; IAAT, intra-abdominal
adipose tissue; LBP, lipopolysaccharide-binding protein; LDL, low-density
lipoprotein; N, number of participants; TAG, triglycerides; WBC, white blood
cells. Data are presented as mean (s.d.).
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inﬂammatory bowel disease.28 Additionally, A. muciniphila has
been shown to alleviate metabolic disturbances in mice on a high-
fat diet, probably due to prevention of a high-fat diet-induced
decrease in the mucus layer and thus bacterial toxin
translocation.29,30 Previously, A. muciniphila has been found to
be more abundant in the gut microbiota of women with normal
weight gain, compared with excessive weight gain during
pregnancy,31 and in normal weight, compared with overweight
children.32 However, it cannot be excluded that these associations
were affected by a lower intake of dietary fat in the normal weight
individuals, as these studies did not correct for the negative
correlation that seem to exist between dietary fat intake and gut
abundance of A. muciniphila (Supplementary Table S4). On the
contrary, a metagenomic study identiﬁed increased abundance
of A. muciniphila in patients with T2D, compared with healthy
individuals.8 However, discrepancy between results could be
explained by differences between study populations, as the study
included patients with diagnosed T2D who might have been in
treatment with anti-diabetic and/or lipid-lowering medication as
opposed to the present study, where T2D and/or dyslipidaemia
were incident. This is supported by studies in mice where the
antidiabetic drug metformin causes an increase in the abundance
of A. muciniphila.30,33 This theory might also explain why Qin et al.8
found increased abundance of B. cellulosilyticus and O. splanchni-
cus in patients with T2D, whereas we ﬁnd these two species to be
associated with a healthy lipid metabolism. The link to a healthy
host metabolism for B. faecis, B. nordii, I. bartlettii and
D. longicatena has not been reported previously, and there are
no recognizable characteristics of these species that may explain
the associations.
B. wadsworthia, C. bolteae, C. mitsuokai, E. ramulus, H. biformis
and R. torques were all positively associated with insulin resistance
or dyslipidaemia, even after covariate adjustment. This is a novel
ﬁnding for the species C. mitsuokai, E. ramulus and H. biformis,
whereas the link to insulin resistance observed for B. wadsworthia
and C. bolteae supports the increased abundance of these bacteria
identiﬁed in patients with T2D.8 The abundance of B. wadsworthia
has also been shown to increase after short-term intake of an
animal-based high-fat diet.14 However, there were no association
between the abundance of B. wadsworthia and habitual dietary
intake of meat, total fat, monounsaturated-, polyunsaturated- or
saturated fatty acids in this study. The mucin-degrading R. torques
has been shown to be more abundant in the gut microbiota of
patients with inﬂammatory bowel disease28 and in individuals
with low microbiome gene richness.5 It is possible that the
positive association with insulin resistance identiﬁed for R. torques
can be explained by a harmful effect of this bacterium on the gut
barrier, leading to metabolic endotoxaemia.34
The results indicate that intake of protein from other dietary
sources than meat is positively correlated with bacterial gene
richness and diversity. This might provide an explanation for the
discrepancies in numbers of individuals with low bacterial richness
identiﬁed between obese cohorts4–6 as the low prevalence of
individuals with low gene count in our study could be due to a
higher habitual intake of non-meat protein.
Previous studies in humans have reported a higher abundance
of Biﬁdobacterium including B. longum in healthy individuals,
Table 2. Correlations between bacterial species and insulin resistance with and without covariate adjustment
Species Glucose (F) Insulin (F) HOMA-IR Matsudas index
Negatively associated with insulin resistance
Bacteroides faecis − 0.38 (0.003) − 0.47 (o0.001) − 0.49 (o0.001) 0.48 (o0.001)
Adj. (age and body fat) − 0.37 (0.004) − 0.47 (o0.001) − 0.48 (o0.001) 0.50 (o0.001)
Adj. (diet) − 0.51 (0.015) − 0.52 (0.002) − 0.56 (o0.001) 0.57 (0.001)
Adj. (full model) − 0.49 (0.014) − 0.51 (0.002) − 0.54 (0.001) 0.63 (0.002)
Biﬁdobacterium longum − 0.44 (0.001) − 0.28 (0.031) − 0.34 (0.012) 0.39 (0.004)
Adj. (age and body fat) − 0.40 (0.011) − 0.31 (0.025) − 0.34 (0.014) 0.43 (0.004)
Adj. (diet) − 0.44 (0.036) − 0.38 (0.563) − 0.42 (0.359) 0.45 (0.205)
Adj. (full model) − 0.40 (0.089) − 0.39 (0.290) − 0.41 (0.205) 0.48 (0.094)
Dorea longicatena − 0.50 (o0.001) − 0.20 (0.090) − 0.28 (0.023) 0.27 (0.035)
Adj. (age and body fat) − 0.49 (o0.001) − 0.29 (0.031) − 0.35 (0.007) 0.40 (0.008)
Adj. (diet) − 0.52 (o0.001) − 0.13 (0.102) − 0.25 (0.025) 0.23 (0.033)
Adj. (full model) − 0.50 (o0.001) − 0.26 (0.048) − 0.32 (0.011) 0.37 (0.011)
Intestinibacter bartlettii − 0.37 (0.006) − 0.30 (0.023) − 0.35 (0.012) 0.37 (0.007)
Adj. (age and body fat) − 0.33 (0.013) − 0.40 (0.024) − 0.40 (0.010) 0.47 (0.018)
Adj. (diet) − 0.60 (0.008) − 0.45 (0.038) − 0.51 (0.019) 0.54 (0.010)
Adj. (full model) − 0.57 (0.010) − 0.54 (0.017) − 0.57 (0.009) 0.63 (0.004)
Positively associated with insulin resistance
Bilophila wadsworthia 0.06 (0.369) 0.36 (0.004) 0.33 (0.008) − 0.32 (0.014)
Adj. (age and body fat) 0.06 (0.255) 0.41 (0.002) 0.38 (0.004) − 0.41 (0.006)
Adj. (diet) 0.14 (0.337) 0.34 (0.005) 0.31 (0.009) − 0.29 (0.013)
Adj. (full model) 0.16 (0.255) 0.39 (0.004) 0.36 (0.006) − 0.39 (0.008)
Clostridium bolteae 0.32 (0.012) 0.36 (0.005) 0.38 (0.003) − 0.35 (0.006)
Adj. (age and body fat) 0.35 (0.005) 0.40 (0.003) 0.42 (0.001) − 0.44 (0.002)
Adj. (diet) 0.34 (0.038) 0.39 (0.017) 0.42 (0.011) − 0.43 (0.025)
Adj. (full model) 0.38 (0.017) 0.43 (0.011) 0.46 (0.006) − 0.51 (0.011)
Eubacterium ramulus 0.40 (0.002) 0.37 (0.004) 0.42 (0.001) − 0.40 (0.002)
Adj. (age and body fat) 0.38 (0.003) 0.41 (0.006) 0.43 (0.002) − 0.46 (0.004)
Ruminococcus torques 0.17 (0.129) 0.39 (0.002) 0.39 (0.003) − 0.39 (0.003)
Adj. (age and body fat) 0.14 (0.115) 0.37 (0.006) 0.36 (0.007) − 0.39 (0.008)
Adj. (diet) 0.24 (0.313) 0.41 (0.010) 0.41 (0.014) − 0.45 (0.015)
Adj. (full model) 0.24 (0.294) 0.40 (0.026) 0.40 (0.030) − 0.47 (0.044)
Abbreviations: F, fasting; HOMA-IR, homeostatic model assessment of insulin resistance. Correlations are presented as Pearson’s r with P-values in parentheses,
with and without adjustment (adj.) for age, body fat, and when relevant; the dietary component with the strongest impact (Supplementary Table S4). Full
models are adjusted for age, body fat and diet.
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compared with individuals with obesity35,36 and T2D,37 and
increased abundance of Biﬁdobacterium has been linked to a
reduction in inﬂammatory markers and an improvement in
glucose homeostasis and lipid metabolism.38–40 However, we
found that the negative correlation between B. longum and both
HOMA-IR and Matsudas index disappeared after adjustment for
carbohydrate intake. Although, the negative correlation with
plasma glucose persisted, this suggests that beneﬁcial effect of
Biﬁdobacterium on host health also depends on dietary intake, and
that beneﬁcial associations identiﬁed between abundance of
Biﬁdobacterium and metabolic health partly reﬂect higher intake of
dietary ﬁbres in healthy individuals. F. prausnitzii A2-165 was
negatively correlated with markers for insulin resistance, but the
negative correlation between F. prausnitzii A2-165 and markers for
insulin resistance disappeared when adjusted for dietary fat
intake. This suggests that the lower abundance of F. prausnitzii
previously reported in individuals with T2D7,8 could be inﬂuenced
by differences in dietary fat intake. However, this cannot be
conﬁrmed as these two studies did not report dietary intake.
Interestingly, we identiﬁed opposing correlations for different
F. prausnitzii strains; F.prausnitzii SL3/3 was positively correlated
with hsCRP but was not associated with markers for insulin
resistance or dietary fat intake, indicating that it is necessary to
evaluate the effects of F. prausnitzii species at the strain level.
As most of the beneﬁcial bacteria identiﬁed in this study appear
to be stimulated by speciﬁc macronutrients (Supplementary Table
S4), a potential approach towards metabolic disease prevention
could combine intake of beneﬁcial bacteria with nutrients that
generate a beneﬁcial gut environment for the bacteria and
improve host health through separate mechanisms. For instance,
dietary supplements with I. bartlettii, B. cellulosilyticus and
B. longum in combination with intake of a diet high in water-
soluble viscous ﬁbres might improve glucose homeostasis and
dyslipidaemia, equally by ﬁbre-induced stimulation of the growth of
these speciﬁc bacteria in the colon and by the gel forming capacity
of the ﬁbres in the gastrointestinal tract that delays gastric emptying
and inhibits absorption of glucose and cholesterol.41
In summary, this study shows that the link between certain gut
bacteria and metabolic risk markers in obesity is independent of
variation in body fat, age and long-term dietary habits, supporting
the use of gut metagenomic markers for metabolic disease
prediction, suggesting a causal role of gut bacteria in develop-
ment of obesity-related metabolic diseases and a potential for
microbiota modulation as a strategy to improve host health. In
addition, the study stresses the importance of a dietary focus
when studying the link between the gut microbiota and metabolic
markers, as it shows that the positive association with a healthy
metabolic proﬁle suggested for B. longum and F. prausnitzii
appears to be modiﬁed by intake of dietary ﬁbre and fat,
respectively. Furthermore, it proposes the search for associations
between dietary components and speciﬁc gut microbiota features
as a strategy for the development of new synbiotic products with
potential for metabolic disease prevention.
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Table 3. Correlations between bacterial species and lipid metabolism with and without covariate adjustment
Species TAG Cholesterol HDL-C LDL-C
Associated with a healthy lipid metabolism
Akkermansia muciniphila − 0.17 (0.120) − 0.42 (0.002) 0.14 (0.826) − 0.37 (0.005)
Adj. (age and body fat) − 0.32 (0.091) − 0.39 (0.002) 0.17 (0.886) − 0.33 (0.006)
Adj. (diet) − 0.17 (0.195) − 0.40 (0.002) 0.21 (0.900) − 0.34 (0.007)
Adj. (full model) − 0.32 (0.156) − 0.37 (0.002) 0.07 (0.926) − 0.29 (0.008)
Bacteroides cellulosilyticus − 0.37 (0.004) − 0.48 (o0.001) − 0.13 (0.781) − 0.38 (0.003)
Adj. (age and body fat) − 0.45 (0.002) − 0.48 (o0.001) − 0.11 (0.883) − 0.37 (0.002)
Adj. (diet) − 0.36 (0.007) − 0.47 (o0.001) − 0.19 (0.748) − 0.38 (0.007)
Adj. (full model) − 0.43 (0.003) − 0.46 (o0.001) − 0.11 (0.875) − 0.36 (0.005)
Bacteroides nordii − 0.24 (0.050) − 0.50 (o0.001) 0.09 (0.458) − 0.46 (o0.001)
Adj. (age and body fat) − 0.30 (0.049) − 0.48 (o0.001) 0.10 (0.437) − 0.44 (o0.001)
Bacteroides pectinophilus − 0.42 (0.001) − 0.42 (0.001) 0.12 (0.199) − 0.47 (o0.001)
Adj. (age and body fat) − 0.53 (o0.001) − 0.41 (o0.001) 0.25 (0.128) − 0.46 (o0.001)
Adj. (diet) − 0.42 (0.002) − 0.40 (0.002) 0.05 (0.167) − 0.45 (o0.001)
Adj. (full model) − 0.52 (o0.001) − 0.39 (0.001) 0.23 (0.100) − 0.45 (o0.001)
Odoribacter splanchnicus − 0.48 (o0.001) − 0.30 (0.016) 0.12 (0.596) − 0.21 (0.072)
Adj. (age and body fat) − 0.53 (o0.001) − 0.26 (0.019) 0.17 (0.346) − 0.17 (0.058)
Roseburia inulinivorans − 0.24 (0.044) − 0.43 (o0.001) − 0.14 (0.801) − 0.35 (0.006)
Adj. (age and body fat) − 0.31 (0.040) − 0.41 (0.001) − 0.11 (0.977) − 0.33 (0.005)
Associated with an unhealthy lipid metabolism
Catenibacterium mitsuokai 0.16 (0.746) 0.45 (0.004) − 0.17 (0.986) 0.43 (0.005)
Adj. (age and body fat) 0.04 (0.639) 0.39 (0.007) − 0.09 (0.805) 0.37 (0.008)
Adj. (diet) 0.17 (0.898) 0.43 (0.008) − 0.24 (0.817) 0.42 (0.010)
Adj. (full model) 0.06 (0.747) 0.36 (0.012) − 0.19 (0.706) 0.35 (0.012)
Holdemanella biformis 0.27 (0.030) 0.49 (o0.001) 0.14 (0.935) 0.44 (o0.001)
Adj. (age and body fat) 0.27 (0.082) 0.46 (o0.001) 0.12 (0.779) 0.41 (o0.001)
Adj. (diet) 0.28 (0.099) 0.49 (o0.001) 0.18 (0.960) 0.43 (0.003)
Adj. (full model) 0.27 (0.183) 0.46 (o0.001) 0.06 (0.762) 0.40 (0.003)
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TAG, triglycerides. Correlations are presented as
Pearson’s r with P-values in parentheses, with and without adjustment (adj.) for age, body fat, and when relevant; the dietary component with the strongest
impact (Supplementary Table S4). Full models are adjusted for age, body fat and diet.
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